Molecular Therapies of Cancer (eBook)

Georg Weber, MD, PhD, is Associate Professor at the James L. Winkle College of Pharmacy at the University of Cincinnati. Dr. Weber has made contributions to metastasis research by discovering the interaction between the molecules osteopontin and CD44 and by defining the physiologic role of metastasis genes as stress response genes. While he continues to address fundamental questions, he is researching new venues for diagnosis and therapy of cancer progression. Dr. Weber's professional affiliations include the American Association for the Advancement of Science, American Medical Association, American Association for Cancer Research, and Metastasis Research Society. Dr. Weber has published several books including Molecular Mechanisms of Cancer, which was published by Springer.

INTRODUCTIONSECTION I: GENERAL PRINCIPLESSECTION II: MOLECULAR TARGETING OF CANCER CELLS1. DNA DAMAGING DRUGS1.1. ALKYLATING AGENTS1.2. ANTIBIOTICS1.3. TOPOISOMERASE INHIBITORS1.4. ANTI-METABOLITES2. DRUGS THAT SUPPRESS PROLIFERATION2.1. ANTI-MITOTIC AGENTS2.2. DIFFERENTIATING AGENTS2.3. INDUCERS OF APOPTOSIS3. MOLECULAR INHIBITORS OF GROWTH SIGNALS3.1. SMALL MOLECULE KINASE INHIBITORS3.2. INHIBITORS OF ONCOGENE FUNCTIONS3.3. ANTIBODIES4. ANTI-METASTASIS THERAPY4.1. INTEGRIN INHIBITORS4.2. CD44 INHIBITORS4.3. MMP INHIBITORS4.4. CHEMOKINE RECEPTOR INHIBITORS4.5. TGF- IHIBITORS4.6. BONE TARGETING AGENTS4.7. OTHERS5. INDUCTION OF SENESCENCE5.1. TELOMERASE INHIBITORS6. COMBINATION CHEMOTHERAPY6.1. TREATMENT OF HEMATOLOGIC MALIGNANCIES6.2. TREATMENT OF SOLID TUMORSSECTION III: EMERGING AND ALTERNATIVE TREATMENT MODALITIES7. GENE THERAPY7.1. GENE SILENCING7.2. SUICIDE GENES7.3. ONCOLYTIC VIRUSES7.4. GENE DELIVERY7.5. OTHER STRATEGIES8. DRUGS WITH DIVERSE MODES OF ACTIONSECTION IV: MOLECULAR TARGETING OF TUMOR-HOST INTERACTIONS9. HORMONE THERAPY9.1. ANTI-ESTROGENS9.2. ANTI-ANDROGENS9.3. CORTICOSTEROIDS10. IMMUNOTHERAPY10.1. IMMUNOTOXINS10.2. ENGINEERED ANTIBODIES10.3. ANTIGEN BASED IMMUNOTHERAPIES10.4. CYTOKINE BASED IMMUNOTHERAPIES10.5. IMMUNE RESPONSE MODIFIERS10.6. AUTOLOGOUS THERAPIES10.7. OTHER REGIMENS11. ANTI-ANGIOGENESIS11.1. VEGF ANTAGONISTS11.2. FGF-2 ANTAGONISTS11.3. THALIDOMIDE RELATED DRUGS11.4. INTEGRIN BLOCKERS11.5. ENDOSTATIN AND ANGIOSTATIN11.6. OTHERSSECTION V: ANTI-CANCER DRUG PHARMACOKINETICS12. DRUG DELIVERY AND DRUG TRANSPORT12.1. TARGETING WITH DRUG CONJUGATES 12.2. RADIO-TARGETING12.3. NANO-PARTICLES12.4. SOLUBILIZERS12.5. VARIOUS13. DRUG METABOLISM13.1. CYP45013.2. FLAVIN MONOOXYGENASES13.3. GST13.4. OTHERS14. PRODRUG ACTIVATION14.1. PHOTODYNAMIC THERAPY14.2. RADIO-SENSITIZATION15. DRUG RESISTANCE15.1. INCREASED EFFLUX15.2. DECREASED UPTAKE 15.3. ANTI-APOPTOSIS15.4. MUTATIONS IN THE DRUG TARGET15.5. ALTERED REPAIR OF DRUG INDUCED DAMAGE15.6. OTHER MECHANISMSSECTION VI: SUPPORTIVE THERAPY16. PROTECTION FROM ADVERSE EFFECTS16.1. ANTI-EMETICS 16.2. PROTECTION FROM ANEMIA16.3. IMMUNE RECOVERY16.4. CARDIOVASCULAR PROTECTION16.5. ANTI-OXIDANTS16.6. ANTI-CACHEXIA DRUGS16.7. PROTECTION FROM HEPATOTOXICITY 16.8. PROTECTION FROM URINARY TOXICITY16.9. PROTECTION OF THE GASTROINTESTINAL TRACT16.10. TREATMENT OF DERMATOLOGIC REACTIONS TO CHEMOTHERAPY 16.11. ELECTROLYTE BALANCE16.12. REPRODUCTIVE PROTECTION16.13. OTHERS17. PAIN MANAGEMENT17.1. NON-STEROIDAL DRUGS17.2. OPIOID DRUGS17.3. OTHERS18. PREVENTIVE TREATMENT18.1. VACCINES18.2. CHEMOPREVENTION